自身免疫性甲状腺疾病与相关miRNAs研究进展
摘要
自身免疫性甲状腺疾病(autoimmune thyroid disease,AITD)是一类器官特异性自身免疫病,以甲状腺淋巴细胞浸润和甲状腺自身抗体产生为主要特征,其确切病因和发病机制尚不明确。miRNAs几乎参与了机体所有的生理和病理过程,研究证明其在自身免疫性甲状腺疾病中发挥了重要作用。AITD患者甲状腺组织及血清中miRNA异常表达,然而这些异常表达miRNA的临床意义尚不明确,其在AITD发生、发展过程中的作用、精准诊断和鉴别诊断中的价值、靶向治疗的可行性、以及在少见类型AITD中的表达特点等,均需要进一步探讨。
引文
1 Wang B,Shao X,Song R,et al. The Emerging role of epigenetics in autoimmune thyroid diseases[J]. Front Immunol,2017,8:396
2 Fabbri M. MicroRNAs and miRceptors:a new mechanism of action for intercellular communication[J]. Philos Trans R Soc Lond B Biol Sci,2018,373(1737):pil 20160486
3 Chen JQ,Papp G,Szodoray P,et al. The microRNAs in the pathogenesis of autoimmune diseases[J]. Autoimmun Rev,2016,15(12):1171-1180
4 Kai K,Dittmar RL,Sen S. Secretory microRNAs as biomarkers of cancer[J]. Semin Cell Dev Biol,2017,19:pii
5 Chen X,Xie D,Zhao Q,et al. MicroRNAs and complex diseases:from experimental results to computational models[J]. Brief Bioinform,2017,
6 Pogribny IP. MicroRNAs as biomarkers for clinical studies[J]. Exp Biol Med(Maywood),2018,243(3):283-290
7 Zhang L,Hou D,Chen X,et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1:evidence ofcross-kingdom regulation by microRNA[J]. Cell Res,2012,22(1):107-126
8 Burch HB,Cooper DS. Management of Graves disease:a review[J]. JAMA,2015,314(23):2544-2554
9 Yamada H,Itoh M,Hiratsuka I,et al. Circulating microRNAs in autoimmune thyroid diseases[J]. Clin Endocrinol(Oxf),2014,81(2):276-281
10 冯绍华,邢双,杨立顺,等.血清microRNA在自身免疫性甲状腺疾病中的潜在诊断价值[J].免疫学杂志,2015,31(8):687-691
11 Chen J,Tian J,Tang X,et al. MiR-346 regulates CD4+CXCR5+T cells in the pathogenesis of Graves disease[J]. Endocrine,2015,49(3):752-760
12 Qin Q,Wang X,Yan N,et al. Aberrant expression of miRNA and mRNAs in lesioned tissues of Graves'disease[J]. Cell Physiol Biochem,2015,35(5):1934-1942
13 Hiratsuka I,Yamada H,Munetsuna E,et al. Circulating microRNAs in Graves'disease in relation to clinical activity[J]. Thyroid,2016,26(10):1431-1440
14 Li J,Cai Y,Sun X,et al. MiR-346 and TRAb as predicative factors for relapse in Graves'disease within one year[J]. Horm Metab Res,2017,49(3):180-184
15 Li K,Du Y,Jiang BL,et al. Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves'ophthalmopathy[J]. Med Sci Monit,2014,20:639-643
16 Tong BD,Xiao MY,Zeng JX,et al. MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy[J]. Mol Vis,2015,21:324-334
17 Shen L,Huang F,Ye L,et al. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves'ophthalmopathy[J]. Endocrine,2015,49(2):445-456
18 Wei H,Guan M,Qin Y,et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves'ophthalmopathy[J]. Endocr J,2014,61(11):1087-1092
19 Ajjan RA,Weetman AP. The pathogenesis of Hashimoto's thyroiditis:further developments in our understanding[J]. Horm Metab Res,2015,47(10):702-710
20 Bernecker C,Halim F,Lenz L,et al. microRNA expressions in CD4and CD8 T-cell subsets in autoimmune thyroid diseases[J]. Exp Clin Endocrinol Diabetes,2014,122(2):107-112
21 Bernecker C,Lenz L,Ostapczuk MS,et al. MicroRNAs miR-146 a1,miR-155-2,and miR-200a1 are regulated in autoimmune thyroid diseases[J]. Thyroid,2012,22(12):1294-1295
22 Zhu J,Zhang Y,Zhang W,et al. MicroRNA-142-5p contributes to Hashimoto's thyroiditis by targeting CLDN1[J]. J Transl Med,2016,14(1):166
23 Caturegli P,De Remigis A,Rose NR. Hashimoto thyroiditis:clinical and diagnostic criteria[J]. Autoimmun Rev,2014,13(4-5):391-397
24 Peng H,Liu Y,Tian J,et al. Decreased expression of microRNA-125 a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis[J]. Immunol Res,2015,62(2):129-136
2 Fabbri M. MicroRNAs and miRceptors:a new mechanism of action for intercellular communication[J]. Philos Trans R Soc Lond B Biol Sci,2018,373(1737):pil 20160486
3 Chen JQ,Papp G,Szodoray P,et al. The microRNAs in the pathogenesis of autoimmune diseases[J]. Autoimmun Rev,2016,15(12):1171-1180
4 Kai K,Dittmar RL,Sen S. Secretory microRNAs as biomarkers of cancer[J]. Semin Cell Dev Biol,2017,19:pii
5 Chen X,Xie D,Zhao Q,et al. MicroRNAs and complex diseases:from experimental results to computational models[J]. Brief Bioinform,2017,
6 Pogribny IP. MicroRNAs as biomarkers for clinical studies[J]. Exp Biol Med(Maywood),2018,243(3):283-290
7 Zhang L,Hou D,Chen X,et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1:evidence ofcross-kingdom regulation by microRNA[J]. Cell Res,2012,22(1):107-126
8 Burch HB,Cooper DS. Management of Graves disease:a review[J]. JAMA,2015,314(23):2544-2554
9 Yamada H,Itoh M,Hiratsuka I,et al. Circulating microRNAs in autoimmune thyroid diseases[J]. Clin Endocrinol(Oxf),2014,81(2):276-281
10 冯绍华,邢双,杨立顺,等.血清microRNA在自身免疫性甲状腺疾病中的潜在诊断价值[J].免疫学杂志,2015,31(8):687-691
11 Chen J,Tian J,Tang X,et al. MiR-346 regulates CD4+CXCR5+T cells in the pathogenesis of Graves disease[J]. Endocrine,2015,49(3):752-760
12 Qin Q,Wang X,Yan N,et al. Aberrant expression of miRNA and mRNAs in lesioned tissues of Graves'disease[J]. Cell Physiol Biochem,2015,35(5):1934-1942
13 Hiratsuka I,Yamada H,Munetsuna E,et al. Circulating microRNAs in Graves'disease in relation to clinical activity[J]. Thyroid,2016,26(10):1431-1440
14 Li J,Cai Y,Sun X,et al. MiR-346 and TRAb as predicative factors for relapse in Graves'disease within one year[J]. Horm Metab Res,2017,49(3):180-184
15 Li K,Du Y,Jiang BL,et al. Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves'ophthalmopathy[J]. Med Sci Monit,2014,20:639-643
16 Tong BD,Xiao MY,Zeng JX,et al. MiRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy[J]. Mol Vis,2015,21:324-334
17 Shen L,Huang F,Ye L,et al. Circulating microRNA predicts insensitivity to glucocorticoid therapy in Graves'ophthalmopathy[J]. Endocrine,2015,49(2):445-456
18 Wei H,Guan M,Qin Y,et al. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves'ophthalmopathy[J]. Endocr J,2014,61(11):1087-1092
19 Ajjan RA,Weetman AP. The pathogenesis of Hashimoto's thyroiditis:further developments in our understanding[J]. Horm Metab Res,2015,47(10):702-710
20 Bernecker C,Halim F,Lenz L,et al. microRNA expressions in CD4and CD8 T-cell subsets in autoimmune thyroid diseases[J]. Exp Clin Endocrinol Diabetes,2014,122(2):107-112
21 Bernecker C,Lenz L,Ostapczuk MS,et al. MicroRNAs miR-146 a1,miR-155-2,and miR-200a1 are regulated in autoimmune thyroid diseases[J]. Thyroid,2012,22(12):1294-1295
22 Zhu J,Zhang Y,Zhang W,et al. MicroRNA-142-5p contributes to Hashimoto's thyroiditis by targeting CLDN1[J]. J Transl Med,2016,14(1):166
23 Caturegli P,De Remigis A,Rose NR. Hashimoto thyroiditis:clinical and diagnostic criteria[J]. Autoimmun Rev,2014,13(4-5):391-397
24 Peng H,Liu Y,Tian J,et al. Decreased expression of microRNA-125 a-3p upregulates interleukin-23 receptor in patients with Hashimoto's thyroiditis[J]. Immunol Res,2015,62(2):129-136